Cognitive Rehabilitation for Post-COVID-19 Cognitive Impairment
Study Details
Study Description
Brief Summary
This pilot randomized controlled trial is to investigate the feasibility and efficacy of cognitive rehabilitation for patients with post-COVID-19 cognitive impairment. Additionally, the study will obtain preliminary data, using rsfMRI, regarding the potential underlying connectivity networks, mediating the effect of CR on cognitive improvements.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Cognitive Rehabilitation Active Group participants will receive nine 1.5-h sessions of virtual (via Zoom platform) group-based training, three individual virtual 1-h training sessions, and approximately 20 h of home practice and CCT over 12 weeks. |
Behavioral: Cognitive Rehabilitation
The virtual small group format will include two to five participants and one facilitator per group. The three individual sessions are distributed at the beginning, middle, and towards the end of the training program. Individual Session 1 occurs after Group Session 1. It covers orientation to the training program, including orientation to and clarification of the Participant Handbook. Individual Session 2 occurs after Group Session 5 and involves review and implementation of training strategies. Individual Session 3 occurs after Group Session 9 and covers review of learned strategies, implementation of training strategies in daily life, and review of execution, obstacles, and adjustments required for individual projects.
|
| Active Comparator: Brain Health Education Program The control group format will be twelve 1.5 or 1 h virtual sessions over 12 weeks, in addition to 20 h of home practice of a computerized control program (e.g., consisting of publicly available computer games such as sudoku and crossword puzzles). |
Behavioral: Brain Health Education Program
The active control group will control for non-specific effects inherent to supervised CR. Participants will receive a manualized brain health education (BHE) training program, matched with the adapted CR intervention for therapist time and homework. Once these participants complete the 12 weeks of the control intervention and undergo the post-intervention assessments, participants will be offered the 12 weeks active intervention to ensure that all study participants have the potential of benefitting from CR.
|
Outcome Measures
Primary Outcome Measures
- Trail Making Test - Part B [end of study, at 12 months]
Trail Making Test - Part B: a measure of aspects of executive functioning (e.g., set- shifting and cognitive flexibility), where participants connect the dots on a page scattered with numbers and letters in alternating sequence. Scored by time in seconds. Higher number of seconds implies deficiencies in cognitive functioning.
- Wisconsin Card Sorting Task (WCST)-64 [end of study, at 12 months]
Wisconsin Card Sorting Task (WCST)-64: Computer Version 2. The WCST-64 is a measure of executive functioning assessing novel problem solving and abstract thinking. The software scores the test and generates percentile scores (0-100). Scored by percentile. Higher percentile implies scoring better than others who have completed the task.
- Acceptability Scale [end of study, at 12 months]
Acceptability: using 7 Likert-rated items (scores will be coded as: Low: ≤3; Moderate: 3-3.9; Good: ≥4). Full range from 1-7, with higher score indicating higher acceptability.
- Enrollment yield [end of study, at 12 months]
Practicality measured by enrollment yield which is #enrolled/approached.
- Dropout number [end of study, at 12 months]
Practicality measured by number of dropout
- Staff Practicality [end of study, at 12 months]
Open-ended questions to staff regarding challenges conducting intervention (e.g., difficulty enrolling, reaching, engaging participants; scores will be coded as: Low: <50%; Moderate: 50-70%; Good: >70%).
- Treatment Credibility and Expectancy Questionnaire. [end of study, at 12 months]
Participants' beliefs about how likely they are to benefit from the intervention using the Treatment Credibility and Expectancy Questionnaire. Full scale from 0-10, with higher score indicating higher treatment expectancy.
- Resting state functional connectivity (rsFC) [end of study, at 12 months]
Neuroimaging Outcomes: Resting state functional connectivity (rsFC) within the central executive network (CEN).
Secondary Outcome Measures
- National Alzheimer's Coordinating Center (NACC) battery's Number Span [end of study, at 12 months]
Participants hear digit sequences of increasing lengths and have to recall them forward and in reversed order. Each level contains two equal number series with different numbers. Max score is 14 points for forward span and 14 points for backwards span. Higher score indicates better performance.
- Paced Auditory Serial Addition Task (PASAT) [end of study, at 12 months]
Single digits are presented every 3 seconds and the participant must add each new digit to the one immediately prior to it. The score is the total number correct out of 60 possible answers. Full scale range from 0-60. Higher scores represent better performance.
- Trail Making Test, Part A [end of study, at 12 months]
Requires participants to connect numbered dots in order as quickly as possible. A higher number of seconds implies worse performance.
- The Symbol Digit Modalities Text (SDMT) [end of study, at 12 months]
Requires an individual to substitute digits for abstract symbols using a reference key as quickly as possible. Reaction times in seconds for the performance of the symbol-digit modalities test. A higher number of seconds implies worse performance.
- The Hopkins Verbal Learning Test-Revised (HVLT-R) [end of study, at 12 months]
A list learning task that assesses learning (immediate recall) and memory (delayed recall) and recognition discrimination. The total score (higher score means a better outcome) is converted to a standardized "T" score using normative data. The possible "T" score for each participant ranges from 20 to 80, with higher scores indicative of better performance.
- NACC battery's verbal phonemic and category fluency tests [end of study, at 12 months]
Requires participants to name as many words as they can beginning with a particular letter in 60 seconds, and then as many animals as they can, respectively. A higher number of words or animals named is indicative of better performance.
- NACC battery's abbreviated Multilingual Naming Test (MINT) [end of study, at 12 months]
The MINT is a research measure intended to assess word retrieval deficits. It requires participants to name a series of individually presented line drawings that range from highly common (e.g. butterfly) to more obscure (e.g., axle) objects. The total scores range from 0 to 32, with higher scores indicating better performance.
- Wide Range Achievement Test, reading subtest, 4th edition (WRAT-4) [end of study, at 12 months]
A measure of premorbid intellectual estimate. Scores range from 0-70, where a higher score indicates greater premorbid intellectual ability.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Adults ≥18 years of age
-
Have a confirmed SARS-CoV-2 infection (positive PCR or are serum antibody positive [against spike protein if unvaccinated or N-capsid peptide if vaccinated])
-
Speak English
-
Have objective mild to moderate cognitive impairment, which will be defined as impairment in executive function (a z-score >1.5 standard deviations below the normative mean) and in at least one other cognitive domain
-
Endorse comfort and familiarity with technology.
Exclusion Criteria:
-
No method of contact
-
Major neurocognitive disorder, as defined by a score <17 on the Montreal Cognitive Assessment (MoCA)
-
History of pre-COVID-19 neurologic disease (e.g., stroke)
-
History of severe head injury (as defined by loss of consciousness >30 minutes)
-
Ongoing substance use disorder (Mini International Neuropsychiatric Interview Version 7.0.2 [MINI] or Alcohol Use Disorders Test-Consumption [AUDIT-C] >8)
-
Unstable medical, neurologic, or psychiatric conditions precluding participation in research activities, and
-
Contraindication for MRI (e.g., metallic/electronic implants).
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Icahn School of Medicine at Mount Sinai | New York | New York | United States | 10029 |
Sponsors and Collaborators
- Icahn School of Medicine at Mount Sinai
Investigators
- Principal Investigator: Juan Wisnivesky, MD, DrPh, Icahn School of Medicine at Mount Sinai
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- STUDY-20-00857